TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03350516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily 500 mg elemental calcium as calcium carbonate
Description: Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily1500 mg elemental calcium as calcium carbonate
Description: Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
Study: NCT02633995

Intervention type: PROCEDURE
Intervention: spinal anaesthesia
Description: regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.

Intervention type: PROCEDURE
Intervention: spinal anaesthesia
Description: regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
Study: NCT05473637

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
Study: NCT06691880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindPod Dolphin VGT
Description: The MindPod Dolphin, is an interactive video game that allows users to engage in non-task-based tasks to motivate the users to play and relearn motor skills. The MindPod gaming platform uses markerless tracking to sense the patient's affected arm. The paretic limb controls Bandit the dolphin underwater in an effort to eat fish. The patient learns to map his/her movements to Bandit in a 3-Dimensional work space to reach the targets. During gaming, the therapist titrates game difficulty. Bilateral gaming components are used (the participant uses a controller with the participant's less-affected limb to control the timing of Bandit's movement) and in-game difficulty can be adjusted to create an immersive, challenging, and engaging experience. In order to be successful, the patient must coordinate both arms to control the temporal and spatial aspects of the game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual Arm Trainer VGT
Description: The bimanual arm trainer (BAT) is a device that involves hardware that interfaces with a computer game. The BAT promotes shoulder external rotation and elbow extension in the paretic arm by coupling movements of the paretic arm with the less affected limb as the participant matches his/her arm movements to those of a virtual avatar. The less-affected side and paretic limb are placed in the BAT apparatus and the less affected limb drives the impaired limb through passive, symmetrical movements that simulate rowing down a virtual river. The protocol created by the investigators group, leads the patient through an active-passive training progression similar to paradigms used in neural priming studies. Through these series of movements, the goal is to restore balance between the muscles of the upper back and chest to maximize range of motion in preparation for improved quality of movement.
Study: NCT06692387

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step count increase with the use of a motivational application
Description: The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational application
Description: The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational application
Description: The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
Study: NCT00968019

Intervention type: DEVICE
Intervention: Presillion stent
Description: Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
Study: NCT02349074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digestive endoscopy
Description: Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
Study: NCT00685035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWC with higher pressure/variable-frequency settings
Description: Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWC with higher pressure/variable-frequency settings
Description: Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWC with lower pressure/mid-frequency settings
Description: Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWC with lower pressure/mid-frequency settings
Description: Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
Study: NCT00493792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X3 Polyethylene
Description: Highly cross-linked polyethylene (HXLPE).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N2Vac Polyethylene
Description: Ultra-high-molecular-weight polyethylene (UHMWPE).
Study: NCT02136238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hosmer 5XA voluntary opening hook
Description: Voluntary opening prosthetic terminal device (hand)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRS Grip 3 voluntary closing hook
Description: Voluntary closing prosthetic terminal device (hand)
Study: NCT02354807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: One-time dose of 100mg of Mirabegron
Study: NCT03402646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder module (SMS and Phone call)
Description: Same as described under arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photovoice
Description: Same as described under arm/group descriptions
Study: NCT01931592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESBL eradication regimen
Description: Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ESBL eradication
Description: Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
Study: NCT02336373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
Study: NCT03145233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise programme
Description: Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic exercise programme
Description: Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
Study: NCT02436304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
Study: NCT00257465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-modified vaccine (M-Vax)
Description: 5.0, 2.5, 0.5, or 0 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-modified vaccine (M-Vax)
Description: 5.0, 2.5, 0.5, or 0 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-modified vaccine (M-Vax)
Description: 5.0, 2.5, 0.5, or 0 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-Modified Melanoma Vaccine
Description: 5 million cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-Modified Vaccine
Description: 2.5 million cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-Modified Vaccine
Description: 0.5 million cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous, DNP-Modified Vaccine
Description: 0 cells
Study: NCT04168697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wim Hof method
Description: 8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wim Hof method
Description: 8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
Study: NCT02400229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (cardiac CT)
Description: Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Description: Clinical management/treatment decisions based on invasive coronary angiography
Study: NCT00532324

Intervention type: OTHER
Group type: OTHER
Intervention: CA-MRSA Decolonization
Description: In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
Study: NCT03921073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-VEC
Description: Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
Study: NCT01349088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Patients will receive ixabepilone at 40 mg/m2.
Study: NCT00699686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Daily bedtime subcutaneous insulin Glargine in individualized doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: Daily bedtime subcutaneous insulin Detemir in individualized doses.
Study: NCT03199417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiprofen
Description: A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
Study: NCT02354807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Exposure of subjects to cold temperature to induce non-shivering thermogenesis
Study: NCT01940263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Study: NCT03199417

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identically packaged placebo cream
Study: NCT05349604

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intake in total
Study: NCT03796104

Intervention type: OTHER
Intervention: Delta-haemolysin
Description: comparison of groups having infection with S. aureus with and without delta-haemolysin Production

Intervention type: OTHER
Intervention: Delta-haemolysin
Description: comparison of groups having infection with S. aureus with and without delta-haemolysin Production
Study: NCT01889251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Study: NCT03923101

Intervention type: DIAGNOSTIC_TEST
Intervention: Topographic, tomographic and biomechanical analysis.
Description: The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA).
Study: NCT06692478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Age 4-6 years: Target lower extremity, core and upper extremity strengthening and activity tolerance. With supervision by the PT, the patient will walk in their room, and complete the following through play: squat, single leg stance, climb onto couch, half kneel to stand, quadruped and tall kneeling.~Age 7-21 years: First component will be strengthening exercises completed in bed or on a mat while sitting or standing. Multiple levels of exercises will be available, so that the program can be tailored to each patient and to their ability to perform activities. The exercises included will focus on core, hip musculature, and upper extremity strengthening; including exercises in quadruped and prone positioning, as well as supine, sitting and standing. Thera-Band will be used to increase resistance as needed. The second component will be endurance. Since the patients will be confined to their room this will include ambulation within the room, recumbent or pedal exerciser and step ups.
Study: NCT03006341

Intervention type: DRUG
Intervention: Dabigatran etexilate
Description: observed upto 12 months

Intervention type: DRUG
Intervention: Warfarin
Description: Observed upto 12 months
Study: NCT01695317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine
Description: Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
Study: NCT01940263

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01695317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetyl-L-carnitine
Description: Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
Study: NCT01501435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30039
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibric acid
Description: single dose
Study: NCT02148406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Skills Training (YST)
Description: Undergo YST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fatigue and depressive symptom assessment and management
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fatigue and depressive symptom assessment and management
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological stress assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychological stress assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study: NCT00003656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study: NCT00392574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Description: Tablet
Study: NCT00003656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin liposome
Study: NCT00825435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiogram
Description: Coronary CT Angiogram
Study: NCT02685280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Restore Advanced 37713
Description: Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
Study: NCT01428895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery Alone
Description: Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Surgery and Radiation therapy
Description: Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
Study: NCT00692562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous islet-kidney transplantation
Study: NCT01341678

Intervention type: DRUG
Group type: OTHER
Intervention: Lanthanum Carbonate
Description: Diet will be supplemented with 1000mg at each meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: NeutraPhos
Description: Diet will be supplemented with NeutraPhos

Intervention type: OTHER
Group type: OTHER
Intervention: Diet Only
Description: Diet containing 1500mg of phosphorus
Study: NCT01486108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dorsal column stimulator
Description: test different settings of stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dorsal column stimulator
Description: test different settings of stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dorsal column stimulator
Description: test different settings of stimulation
Study: NCT00760786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lipid lowering plus Omega3-fatty acid
Description: Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate lipid lowering plus Omega3-fatty acid
Description: atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lipid lowering plus placebo
Description: atorvastatin 40mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate lipid lowering plus placebo
Description: atorvastatin 10mg qd
Study: NCT03671187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise program
Study: NCT02237547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
Study: NCT02770144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
Study: NCT00392574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet